Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC).-Reference-Cited by-同舟云学术

Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC).

Published:2015-05-20 Issue:15_suppl Volume:33 Page:103-103
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Atreya Chloe Evelyn¹,Van Cutsem Eric²,Bendell Johanna C.³,Andre Thierry⁴,Schellens Jan H. M.⁵,Gordon Michael S.⁶,McRee Autumn Jackson⁷,O'Dwyer Peter J⁸,Muro Kei⁹,Tabernero Josep¹⁰,van Geel Robin¹¹,Sidhu Roger¹²,Greger James G¹³,Rangwala Fatima A.¹⁴,Motwani Monica¹³,Wu Yuehui¹⁵,Orford Keith W.¹³,Corcoran Ryan Bruce¹⁶

Affiliation:

1. University of California, San Francisco, San Francisco, CA

2. University Hospitals Leuven, Leuven, Belgium

3. Sarah Cannon Research Institute, Nashville, TN

4. St Antoine Hospital, Paris, France

5. The Netherlands Cancer Institute, Amsterdam, Netherlands

6. Pinnacle Oncology Hematology, Scottsdale, AZ

7. Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC

8. University of Pennsylvania, Philadelphia, PA

9. Aichi Cancer Center Hospital, Nagoya, Japan

10. Vall d’Hebron University Hospital, Barcelona, Spain

11. The Netherlands Cancer Institute, Antoni Van Leeuwenhoek Hospital, Amsterdam, Netherlands